DiaSys Continues International Expansion Through Entrance Into Australian Market; Company Selects Laboratory Diagnostics To Distribute Diagnostics Products in Country
DiaSys Corporation (AMEX:DYX) a global diagnostics products company, announced today that it has entered into a distribution agreement with Laboratory Diagnostics Pty Ltd., a leading distributor of niche market testing products for both the human and veterinary diagnostic industry in Australia and New Zealand. Based in Sydney with regional offices in Brisbane and Melbourne, Laboratory Diagnostics represents the leading suppliers of diagnostics from Europe and America.
“We continue to rapidly expand into many promising markets,” said Greg Witchel, DiaSys Corporation’s Chief Executive Officer. “Australia represents a lucrative market, due to the strong sales in the country of animal diagnostic products. The choice of a highly successful distributor such as Laboratory Diagnostics will enable us to rapidly identify and penetrate many of the leaders in the medical industry. In the past two months, we have entered promising markets in Latin America and now Australia. We believe that these initiatives will favorably impact our revenue next year.”
Laboratory Diagnostics represents leading international human diagnostics companies in the country such as Binax Inc., Alfa Scientific, R Biopharm and Diesse Diagnostica. It also distributes products for such veterinary companies as Institut Pourquier, Synbiotics, VMRD, BIOX Diagnostics and Biogal.
DiaSys Corporation designs, develops, manufactures and distributes proprietary medical laboratory equipment, consumables and infectious disease test kits to healthcare and veterinary laboratories worldwide. Headquartered in Waterbury, Connecticut, the Company operates in Europe through its wholly owned subsidiary based in Wokingham, England. DiaSys, Parasep and Urisep are registered trademarks of DiaSys Corporation.
